Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY: OGEN )

0.2800 -0.0072 (-2.51%)
Official Closing Price Updated: 8:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oragenics Inc. Common Stock

< Previous 1 2 3 Next >
BioMedNewsBreaks — Oragenics Inc. Advances Concussion Treatment with Phase II Trial Preparation
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Highlights Concussion Treatment Advances at Emergencies in Medicine Conference
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Appoints Chief Medical Officer to Medical Board of The Leigh Steinberg Foundation
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Partners With BRAINBox Solutions to Advance Concussion Care
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Chief Medical Officer to Speak at Brain Health Summit During Super Bowl Week
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Advances ONP-002 Development, Appoints Janet Huffman as Interim CEO
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Streamlines Capital Structure with Preferred Stock Conversion
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Oragenics to Present at Centurion One Capital 2nd Annual Bahamas Summit
Via Investor Brand Network
BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Closes on $4.45M Public Offering
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
Exposures Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
From Oragenics, Inc.
Via Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Closing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Pricing of Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Proposed Public Offering
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Leadership Transition
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
From Oragenics, Inc.
Via Business Wire
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
From Oragenics, Inc.
Via Business Wire
Oragenics Announces Termination of At-The-Market Offering Program
From Oragenics, Inc.
Via Business Wire
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
From Oragenics, Inc.
Via Business Wire
Oragenics Issues Update to Shareholders
From Oragenics
Via Business Wire
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
From Oragenics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.